Metsera rises after Novo Nordisk and Pfizer sweeten bids

Metsera

04/11/2025 15:08

Amends fourth bullet after Metsera corrects Novo's previous CVR offer to $21.25 from $22.50

** Shares of weight loss drug developer Metsera MTSR.O rise 12.7% to $68.64

** Novo Nordisk NOVOb.CO and Pfizer PFE.N have revised their bids for Metsera, co says

** Novo's revised offer brings the deal value to about $10 billion, while Pfizer is now willing to shell out $8.1 billion

** As per Novo's new offer, Metsera is also eligible to receive an additional $24.00 per share in cash, up from $21.25, based on development and regulatory approval milestones

** Pfizer has filed two lawsuits against Metsera, its board, and Novo Nordisk

** Including session moves, MTSR has more than doubled since its stock market debut in January

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))